-
Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of Hu-mAtrIx, an innovative AI-assisted drug discovery engine. This platform marks a significant advancement in the field of antibody development, leveraging cutting-edge technology to enhance efficiency and success rates. Integrated Antibody Discovery PlatformNona’s Hu-mAtrIx platform enables…
-
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a licensing agreement with the University of Alabama at Birmingham (UAB) to support research in B cell development. Agreement DetailsUnder the agreement, Dr. James Kobie of UAB will receive a non-exclusive license to develop fully human…
-
Nona Biosciences Partners with Invetx for Animal Health Therapies
•
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership with US-based animal health company Invetx, Inc. Under the agreement, Invetx will utilize Nona’s HCAb Harbour Mice platform to develop next-generation biological therapies for animal health. Financial details of the partnership were not disclosed. Significance…
-
Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment
•
US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell engagers (TCEs) for B-cell depletion to treat autoimmune diseases, with the signing of Chinese firms Nona Biosciences and EpimAb Biotherapeutics, Inc., as well as compatriot firm Ab Studio, Inc., in a single day to strengthen…
-
Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with US-based Kodiak Sciences lnc. (NASDAQ: KOD) in a strategic partnership aimed at advancing the discovery of novel multi-target antibodies to treat ophthalmic diseases. The collaboration will leverage Nona Bio’s proprietary Harbour Mice fully human antibody…
-
Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a partnership with US biotechnology company OverT Bio, Inc. to develop next-generation cell therapies targeting solid tumors. The collaboration will leverage Nona’s heavy-chain antibody (HCAb) Harbour Mice platform, with no financial specifics disclosed. Nona Bio’s HCAb…
-
Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic partnership with U.S. biotechnology company Alkyon Therapeutics, Inc. (AlkyonTx). The collaboration aims to develop next-generation immunotherapy and other targeted therapy applications, leveraging Nona’s proprietary Harbour Mice fully human antibody platform. The financial details of the…
-
Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic collaboration with US-based Umoja Biopharma to co-develop multi-target antibody therapies. The partnership will leverage Nona’s proprietary fully human heavy chain only antibody (HCAb) technology to create innovative CAR-T cell therapy drug candidates generated in vivo.…
-
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic cooperation agreement with Alaya.bio, a France-based polymer delivery platform company. This collaboration aims to harness their respective strengths to streamline the development, manufacturing, and administration of chimeric antigen receptor (CAR)-T therapies through precision targeting and…
-
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
•
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement with the UK pharmaceutical giant AstraZeneca. The deal revolves around a pre-clinical monoclonal antibody (mAb) program, marking a substantial step forward in the development of innovative therapies. Under the terms of the agreement, AstraZeneca will…
-
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have jointly announced the licensing of their co-developed antibody-drug conjugate (ADC), HBM9033 (YL215), to Pfizer Inc.’s (NYSE: PFE) unit Seagen Inc. (NASDAQ: SGEN). According to the agreement, Seagen will secure global clinical development and commercialization rights…
-
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona’s proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for…
-
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery…
-
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not…
-
Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has announced a strategic partnership with OPKO Health’s subsidiary, ModeX Therapeutics. The collaboration will fully leverage Nona Bio’s Harbor Mice whole human transgenic mouse platform technology for the development…
-
Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with PharmaEssentia Corp.’s R&D center in Boston, United States. The collaboration will fully utilize Nona Bio’s Harbor Mice whole human transgenic mouse platform technology for biomedicine research and development, marking a significant step in…
-
Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the Netherlands, the United States, and China, has struck a partnership with Dr. Michael S. Diamond from Washington University School of Medicine in St. Louis. This collaboration aims to explore viral disease fields that are currently…
-
Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with Belgium-based ExeVir Bio. The collaboration aims to explore the infectious disease sector, with no financial details or other specifics disclosed at this time. ExeVir Bio’s Nanoantibody-Based Therapy PlatformExeVir Bio is a clinical biotechnology…
-
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
•
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio’s proprietary All H2L2 transgenic Harbour Mice platform…
-
Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
•
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a licensing deal with US firm Dragonfly Therapeutics. The agreement grants Dragonfly rights to use Nona Bio’s heavy chain only antibody discovery platform (HCAb) technology and develop antibodies according to Dragonfly’s designated targets. Financial details…
